{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T22:18:16Z","timestamp":1648851496642},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,3,22]],"date-time":"2013-03-22T00:00:00Z","timestamp":1363910400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1007\/s40262-013-0043-z","type":"journal-article","created":{"date-parts":[[2013,3,21]],"date-time":"2013-03-21T10:32:13Z","timestamp":1363861933000},"page":"359-371","source":"Crossref","is-referenced-by-count":3,"title":["Quantifying the Effect of Covariates on Concentrations and Effects of Steady-State Phenprocoumon Using a Population Pharmacokinetic\/Pharmacodynamic Model"],"prefix":"10.1007","volume":"52","author":[{"given":"Khaled","family":"Abduljalil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Lazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Natanzon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weidong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregor","family":"Zadoyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedict","family":"Steffens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Kohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"M\u00f6rike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorota","family":"Tomalik-Scharte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Stingl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Job","family":"Harenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Gleiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Fuhr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,3,22]]},"reference":[{"key":"43_CR1","unstructured":"Bourgain R, Wright IS. Marcumar, a new anticoagulant. Revue d\u2019hematologie. 1955;10(2):387\u20139 (discussion 412\u201322)."},{"issue":"1","key":"43_CR2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/BF00610379","volume":"33","author":"D Trenk","year":"1987","unstructured":"Trenk D, Althen H, Jahnchen E, et al. Factors responsible for interindividual differences in the dose requirement of phenprocoumon. Eur J Clin Pharmacol. 1987;33(1):49\u201354.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5 Suppl","key":"43_CR3","doi-asserted-by":"crossref","first-page":"445S","DOI":"10.1378\/chest.114.5_Supplement.445S","volume":"114","author":"J Hirsh","year":"1998","unstructured":"Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1998;114[Suppl 5]:445S\u201369S.","journal-title":"Chest"},{"issue":"9","key":"43_CR4","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2165\/00003088-200847090-00002","volume":"47","author":"S Stehle","year":"2008","unstructured":"Stehle S, Kirchheiner J, Lazar A, et al. Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin Pharmacokinet. 2008;47(9):565\u201394.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"43_CR5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/sj.clpt.6100036","volume":"81","author":"T Schalekamp","year":"2007","unstructured":"Schalekamp T, Brasse BP, Roijers JF, et al. VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement. Clin Pharmacol Ther. 2007;81(2):185\u201393.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"43_CR6","first-page":"192","volume":"32","author":"KO Haustein","year":"1994","unstructured":"Haustein KO, Huller G. Pharmacokinetics of phenprocoumon. Int J Clin Pharmacol Ther. 1994;32(4):192\u20137.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"43_CR7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1024\/0040-5930.60.1.5","volume":"60","author":"L Alberio","year":"2003","unstructured":"Alberio L. Oral anticoagulation with vitamin K antagonists (in German). Ther Umsch. 2003;60(1):5\u20139.","journal-title":"Ther Umsch"},{"issue":"11","key":"43_CR8","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s002280050567","volume":"54","author":"UP Masche","year":"1999","unstructured":"Masche UP, Rentsch KM, von Felten A, et al. Opposite effects of lornoxicam co-administration on phenprocoumon pharmacokinetics and pharmacodynamics. Eur J Clin Pharmacol. 1999;54(11):857\u201364.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"43_CR9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0378-4347(00)83858-X","volume":"529","author":"JX Vries de","year":"1990","unstructured":"de Vries JX, Volker U. Determination of the plasma protein binding of the coumarin anticoagulants phenprocoumon and its metabolites, warfarin and acenocoumarol, by ultrafiltration and high-performance liquid chromatography. J Chromatogr. 1990;529(2):479\u201385.","journal-title":"J Chromatogr"},{"issue":"11","key":"43_CR10","first-page":"891","volume":"51","author":"S Russmann","year":"2001","unstructured":"Russmann S, Dilger K, Trenk D, et al. Effect of lysine clonixinate on the pharmacokinetics and anticoagulant activity of phenprocoumon. Arzneimittel-Forschung. 2001;51(11):891\u20135.","journal-title":"Arzneimittel-Forschung"},{"issue":"1","key":"43_CR11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00008571-200401000-00002","volume":"14","author":"J Kirchheiner","year":"2004","unstructured":"Kirchheiner J, Ufer M, Walter EC, et al. Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers. Pharmacogenetics. 2004;14(1):19\u201326.","journal-title":"Pharmacogenetics"},{"issue":"1","key":"43_CR12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF00546711","volume":"26","author":"NR Kitteringham","year":"1984","unstructured":"Kitteringham NR, Bustgens L, Brundert E, et al. The effect of liver cirrhosis on the pharmacokinetics of phenprocoumon. Eur J Clin Pharmacol. 1984;26(1):65\u201370.","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"43_CR13","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/jps.2600741003","volume":"74","author":"S Toon","year":"1985","unstructured":"Toon S, Heimark LD, Trager WF, et al. Metabolic fate of phenprocoumon in humans. J Pharm Sci. 1985;74(10):1037\u201340.","journal-title":"J Pharm Sci"},{"issue":"4","key":"43_CR14","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/BF00561379","volume":"35","author":"JX Vries de","year":"1988","unstructured":"de Vries JX, Raedsch R, Volker U, et al. Biliary excretion of phenprocoumon and metabolites. Eur J Clin Pharmacol. 1988;35(4):433\u20136.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"43_CR15","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s00216-005-0113-7","volume":"383","author":"B Kammerer","year":"2005","unstructured":"Kammerer B, Kahlich R, Ufer M, et al. Stereospecific pharmacokinetic characterisation of phenprocoumon metabolites, and mass-spectrometric identification of two novel metabolites in human plasma and liver microsomes. Anal Bioanal Chem. 2005;383(6):909\u201317.","journal-title":"Anal Bioanal Chem"},{"issue":"3","key":"43_CR16","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00228-004-0740-5","volume":"60","author":"M Ufer","year":"2004","unstructured":"Ufer M, Svensson JO, Krausz KW, et al. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur J Clin Pharmacol. 2004;60(3):173\u201382.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"43_CR17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1006\/abbi.1999.1468","volume":"372","author":"M He","year":"1999","unstructured":"He M, Korzekwa KR, Jones JP, et al. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. Arch Biochem Biophys. 1999;372(1):16\u201328.","journal-title":"Arch Biochem Biophys"},{"issue":"12","key":"43_CR18","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.2165\/00003088-200544120-00003","volume":"44","author":"M Ufer","year":"2005","unstructured":"Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet. 2005;44(12):1227\u201346.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"43_CR19","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-199410050-00003","volume":"10","author":"MD Freedman","year":"1994","unstructured":"Freedman MD, Olatidoye AG. Clinically significant drug interactions with the oral anticoagulants. Drug Saf. 1994;10(5):381\u201394.","journal-title":"Drug Saf"},{"issue":"2","key":"43_CR20","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0378-4347(00)82337-3","volume":"530","author":"PM Edelbroek","year":"1990","unstructured":"Edelbroek PM, van Kempen GM, Hessing TJ, et al. Analysis of phenprocoumon and its hydroxylated and conjugated metabolites in human urine by high-performance liquid chromatography after solid-phase extraction. J Chromatogr. 1990;530(2):347\u201358.","journal-title":"J Chromatogr"},{"issue":"5","key":"43_CR21","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.clpt.2004.08.006","volume":"76","author":"T Schalekamp","year":"2004","unstructured":"Schalekamp T, Oosterhof M, van Meegen E, et al. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status. Clin Pharmacol Ther. 2004;76(5):409\u201317.","journal-title":"Clin Pharmacol Ther"},{"key":"43_CR22","doi-asserted-by":"crossref","unstructured":"Ufer M. Effects of CYP2C9 polymorphisms on phenprocoumon anticoagulation status. Clin Pharmacol Ther. 2005;77(4):335\u20136 (author reply 6).","DOI":"10.1016\/j.clpt.2005.01.012"},{"issue":"15","key":"43_CR23","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1093\/eurheartj\/ehr116","volume":"32","author":"RM Schie van","year":"2011","unstructured":"van Schie RM, Wessels JA, le Cessie S, et al. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur Heart J. 2011;32(15):1909\u201317.","journal-title":"Eur Heart J"},{"issue":"1","key":"43_CR24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/FPC.0b013e32834154fb","volume":"21","author":"M Teichert","year":"2011","unstructured":"Teichert M, Eijgelsheim M, Uitterlinden AG, et al. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes. Pharmacogenetics Genomics. 2011;21(1):26\u201334.","journal-title":"Pharmacogenetics Genomics"},{"issue":"4","key":"43_CR25","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00228-010-0950-y","volume":"67","author":"C Geisen","year":"2011","unstructured":"Geisen C, Luxembourg B, Watzka M, et al. Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters. Eur J Clin Pharmacol. 2011;67(4):371\u201381.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"43_CR26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00228-009-0768-7","volume":"66","author":"J Cadamuro","year":"2010","unstructured":"Cadamuro J, Dieplinger B, Felder T, et al. Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. Eur J Clin Pharmacol. 2010;66(3):253\u201360.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"43_CR27","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2008-04-149070","volume":"113","author":"M Wadelius","year":"2009","unstructured":"Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood. 2009;113(4):784\u201392.","journal-title":"Blood"},{"issue":"1","key":"43_CR28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clpt.2006.04.006","volume":"80","author":"T Schalekamp","year":"2006","unstructured":"Schalekamp T, Brasse BP, Roijers JF, et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther. 2006;80(1):13\u201322.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"43_CR29","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/clpt.2008.294","volume":"85","author":"M Teichert","year":"2009","unstructured":"Teichert M, van Schaik RH, Hofman A, et al. Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period. Clin Pharmacol Ther. 2009;85(4):379\u201386.","journal-title":"Clin Pharmacol Ther"},{"key":"43_CR30","doi-asserted-by":"crossref","unstructured":"Werner D, Werner U, Wuerfel A, et al. Pharmacogenetic characteristics of patients with complicated phenprocoumon dosing. Eur J Clin Pharmacol. 2009; 65:783\u20138.","DOI":"10.1007\/s00228-009-0639-2"},{"issue":"10","key":"43_CR31","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1371\/journal.pmed.0020312","volume":"2","author":"PH Reitsma","year":"2005","unstructured":"Reitsma PH, van der Heijden JF, Groot AP, et al. A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med. 2005;2(10):e312.","journal-title":"PLoS Med"},{"issue":"3","key":"43_CR32","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00228-009-0768-7","volume":"66","author":"J Cadamuro","year":"2011","unstructured":"Cadamuro J, Dieplinger B, Felder T, et al. Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. Eur J Clin Pharmacol. 2011;66(3):253\u201360.","journal-title":"Eur J Clin Pharmacol"},{"key":"43_CR33","volume-title":"NONMEM Users Guides, (1989\u20132006)","author":"SL Beal","year":"2008","unstructured":"Beal SL, Sheiner LB. NONMEM Users Guides, (1989\u20132006). Ellicott: Icon Development Solutions; 2008."},{"key":"43_CR34","doi-asserted-by":"crossref","unstructured":"Holford N. Input\u2013output models. In: Kimko HC, Duffull SB, editors. Simulation for designing clinical trials: a pharmacokinetic\u2013pharmacodynamic perspective, vol. 125. New York: Marcel Dekker; 2002. p. 2\u201331.","DOI":"10.1201\/9780203910276.ch2"},{"issue":"4","key":"43_CR35","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/BF01061662","volume":"19","author":"PO Maitre","year":"1991","unstructured":"Maitre PO, Buhrer M, Thomson D, et al. A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam. J Pharmacokinet Biopharm. 1991;19(4):377\u201384.","journal-title":"J Pharmacokinet Biopharm"},{"key":"43_CR36","unstructured":"European Medicines Agency (EMA) Committee for Human Medicinal Products (CHMP). Guideline on the Investigation of Drug Interactions. CPMP\/EWP\/560\/95\/Rev. 1. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/07\/WC500129606.pdf . Accessed 15 Sept 2012."},{"issue":"6","key":"43_CR37","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/BF02353461","volume":"23","author":"EI Ette","year":"1995","unstructured":"Ette EI, Kelman AW, Howie CA, et al. Analysis of animal pharmacokinetic data: performance of the one point per animal design. J Pharmacokinet Biopharm. 1995;23(6):551\u201366.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"1","key":"43_CR38","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1055\/s-0038-1661257","volume":"53","author":"EA Loeliger","year":"1985","unstructured":"Loeliger EA, van den Besselaar AM, Lewis SM. Reliability and clinical impact of the normalization of the prothrombin times in oral anticoagulant control. Thromb Haemost. 1985;53(1):148\u201354.","journal-title":"Thromb Haemost"},{"issue":"2","key":"43_CR39","first-page":"217","volume":"809","author":"M Ufer","year":"2004","unstructured":"Ufer M, Kammerer B, Kirchheiner J, et al. Determination of phenprocoumon, warfarin and their monohydroxylated metabolites in human plasma and urine by liquid chromatography\u2013mass spectrometry after solid-phase extraction. J Chromatogr. 2004;809(2):217\u201326.","journal-title":"J Chromatogr"},{"issue":"6","key":"43_CR40","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0010-4809(69)90030-5","volume":"2","author":"LB Sheiner","year":"1969","unstructured":"Sheiner LB. Computer-aided long-term anticoagulation therapy. Comput Biomed Res Int J. 1969;2(6):507\u201318.","journal-title":"Comput Biomed Res Int J"},{"key":"43_CR41","unstructured":"Holford NH. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clin Pharmacokinet. 1986;11(6):483\u2013504."},{"issue":"4","key":"43_CR42","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1136\/jcp.2007.052498","volume":"61","author":"DJ Harrington","year":"2008","unstructured":"Harrington DJ, Western H, Seton-Jones C, et al. A study of the prevalence of vitamin K deficiency in patients with cancer referred to a hospital palliative care team and its association with abnormal haemostasis. J Clin Pathol. 2008;61(4):537\u201340.","journal-title":"J Clin Pathol"},{"issue":"3","key":"43_CR43","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00228-003-0580-8","volume":"59","author":"E Hummers-Pradier","year":"2003","unstructured":"Hummers-Pradier E, Hess S, Adham IM, et al. Determination of bleeding risk using genetic markers in patients taking phenprocoumon. Eur J Clin Pharmacol. 2003;59(3):213\u20139.","journal-title":"Eur J Clin Pharmacol"},{"key":"43_CR44","doi-asserted-by":"crossref","unstructured":"Qazim B, Stollberger C, Krugluger W, et al. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1 and CYP2C9 genes. J Thromb Thrombolysis. 2009;28(2):211\u20134.","DOI":"10.1007\/s11239-008-0252-8"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-013-0043-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-013-0043-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-013-0043-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T05:50:37Z","timestamp":1562824237000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-013-0043-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,22]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["43"],"URL":"https:\/\/doi.org\/10.1007\/s40262-013-0043-z","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,22]]}}}